Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior

Inflammatory Bowel Diseases

Volumn 17, Issue 12, 2011, Pages 2488-2496

  Lichtenstein, Gary R ^a   Targan, Stephan R ^b   Dubinsky, Marla C ^b   Rotter, Jerome I ^b   Barken, Derren M ^c   Princen, Fred ^c   Carroll, Susan ^c   Brown, Michelle ^c   Stachelski, Jordan ^c   Chuang, Emil ^c   Landers, Carol J ^b   Stempak, Joanne M ^d   Singh, Sharat ^c   Silverberg, Mark S ^d  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Prometheus Laboratories Inc   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

complications; Crohn's disease; genetics; NOD2; serology

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CBIR1 ANTIBODY; I2 ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; OUTER MEMBRANE PROTEIN C ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CHILD; CROHN DISEASE; FEMALE; FOLLOW UP; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNE RESPONSE; INTESTINE INJURY; INTESTINE STENOSIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; YOUNG ADULT;

EID: 80855128813     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21661     Document Type: Article

References (39)

1. Voices of Progress Annual Report 2008 [CCFA Web site]. August 31, 2008. Available at:. Accessed March 8, 2010.
2. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol. 2006; 101: 1559-1568. (Pubitemid 43980630)
3. Wolters FL, Russel MG, Sijbrandij J, et al. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol Suppl. 2006; 243: 46-54. (Pubitemid 43941066)
4. Loftus EV, Schoenfeld P, Sandborn WJ,. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002; 16: 51-60. (Pubitemid 34123864)
5. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001; 49: 777-782. (Pubitemid 33096034)
6. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8: 244-250. (Pubitemid 34784976)
7. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006; 130: 650-656. (Pubitemid 43374514)
8. Romberg-Camps MJL, Dagnelie PC, Kester ADM, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009; 104: 371-383.
9. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology. 1994; 106: 643-648. (Pubitemid 24064330)
10. Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology. 1996; 110: 424-431. (Pubitemid 26043875)
11. Hanauer SB,. Positioning biologic agents in the treatment of Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1570-1582.
12. D'Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660-667. (Pubitemid 351284485)
13. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010; 138: 463-468.
14. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004; 99: 2376-2384. (Pubitemid 40039369)
15. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004; 126: 414-424. (Pubitemid 38182298)
16. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000; 47: 487-496
17. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005; 128: 2020-2028. (Pubitemid 40824710)
18. Lichtenstein GR,. Emerging prognostic markers to determine Crohn's disease natural history and improve management strategies: a review of recent literature. Gastroenterol Hepatol. 2010; 6: 99-107.
19. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006; 101: 360-367. (Pubitemid 43381681)
20. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008; 40: 955-962.
21. Devlin SM, Yang H, Ippoliti A, et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology. 2007; 132: 576-586. (Pubitemid 46274655)
22. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002; 123: 679-688. (Pubitemid 34977073)
23. Cho JH, Abraham C,. Inflammatory bowel disease genetics: NOD2. Annu Rev Med. 2007; 58: 401-416. (Pubitemid 46706523)
24. Maeda S, Hsu LC, Liu H, et al. NOD2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science. 2005; 307: 734-738. (Pubitemid 40194645)
25. Girardin SE, Boneca IG, Viala J, et al. NOD2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003; 278: 8869-8872. (Pubitemid 36800360)
26. Annese V, Lombardi G, Perri F, et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn's Disease - an IG-IBD study. Am J Gastroenterol. 2005; 100: 84-92. (Pubitemid 41623274)
27. Heliö T, Halme L, Lappalainen M, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut. 2003; 52: 558-562. (Pubitemid 36363411)
28. Ippoliti A, Devlin S, Mei L, et al. Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. Inflamm Bowel Dis. 2010; 16: 1279-1285.
29. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (suppl A): 5-36.
30. Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology. 2000; 119: 23-31. (Pubitemid 30452575)
31. Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol. 1996; 3: 219-226. (Pubitemid 26104780)
32. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004; 113: 1296-1306. (Pubitemid 39069929)
33. Cohavy O, Bruckner D, Gordon LK, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun. 2000; 68: 1542-1548. (Pubitemid 30108556)
34. Vidrich A, Lee J, James E, et al. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol. 1995; 15: 293-299.
35. Harrell FE Jr,. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
36. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008; 6: 1105-1111.
37. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002; 123: 689-699. (Pubitemid 34977074)
38. Desir B, Amre DK, Lu S-E, et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol. 2004; 2: 139-146. (Pubitemid 38180468)
39. Rieder F, Schleder S, Wolf A, et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis. 2010; 16: 1367-1375.